You may hear CD markers called antigens ... disease courses and respond differently to treatments: Diffuse large B cell lymphoma (DLBCL) is cancer involving B cells. Under the microscope, the ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse large B-cell lymphoma (DLBCL). The CD20xCD3 T-cell engaging bispecific ...

Roche announced that the European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory ...